BCX7353, a Potent Inhibitor of Plasma Kallikrein, Shows Sustained Maximal Enzyme Inhibition When Dosed Orally Once Daily: Results From a Phase I Trial in Healthy Subjects

Journal of Allergy and Clinical Immunology - United States
doi 10.1016/j.jaci.2015.12.1243
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Sustained-Release Ruxolitinib: Findings From a Phase 1 Study in Healthy Subjects and a Phase 2 Study in Patients With Myelofibrosis

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2018English

Pharmacodynamic and Pharmacokinetic Profile of S 17092, a New Orally Active Prolyl Endopeptidase Inhibitor, in Elderly Healthy Volunteers. A Phase I Study

British Journal of Clinical Pharmacology
Pharmacology
2001English

Single-Dose Pharmacokinetics of Co-Crystal of Tramadol-Celecoxib: Results of a 4-Way Randomized Open-Label Phase I Clinical Trial in Healthy Subjects

British Journal of Clinical Pharmacology
Pharmacology
2017English

Inhalation of a Dry Powder Ciprofloxacin Formulation in Healthy Subjects: A Phase I Study

Clinical Drug Investigation
MedicinePharmacology
2013English

Effect of Diet on Serum Creatinine in Healthy Subjects During a Phase I Study

Journal of Clinical Medicine Research
2016English

The EZH2 Inhibitor Tazemetostat Is Well Tolerated in a Phase I Trial

Cancer Discovery
Oncology
2018English

TAS4464, a Highly Potent and Selective Inhibitor of NEDD8 Activating Enzyme, Suppresses Neddylation and Shows Antitumor Activity in Diverse Cancer Models

Molecular Cancer Therapeutics
Cancer ResearchOncology
2019English

Pharmacokinetic Profiles of a Biosimilar Filgrastim and Amgen Filgrastim: Results From a Randomized, Phase I Trial

Annals of Hematology
MedicineHematology
2010English

Gene Therapy for Pain: Results of a Phase I Clinical Trial

Annals of Neurology
Neurology
2011English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy